Standout Papers

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in ... 2005 2026 2012 2019 1.1k
  1. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005)
    Michel Marty, Francesco Cognetti et al. IRIS UNIMORE (University of Modena and Reggio Emilia)

Immediate Impact

6 by Nobel laureates 13 from Science/Nature 75 standout
Sub-graph 1 of 18

Citing Papers

Natural killer cell therapies
2024 StandoutNature
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
1 intermediate paper

Works of Jean-Marc Extra being referenced

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005 Standout
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
2005

Author Peers

Author Last Decade Papers Cites
Jean-Marc Extra 2184 1059 587 747 50 3.0k
RD Gelber 1643 901 498 459 37 2.7k
Claire Barton 1997 805 504 676 39 2.7k
B. Ojeda 1842 1055 372 682 57 2.7k
Debra Frye 2421 1637 366 473 35 3.2k
Timothy G. Cooke 1881 894 399 982 64 3.4k
M. Tubiana-Hulin 3192 1639 852 861 59 4.5k
Brigitte Mlineritsch 2020 1080 573 440 70 2.7k
Vichien Srimuninnimit 2778 1615 1498 773 65 3.6k
Hans‐Joachim Lück 1833 705 559 293 66 2.8k
Virginia McNally 2456 953 636 848 37 2.9k

All Works

Loading papers...

Rankless by CCL
2026